REDHILL BIOPHARMA LTD. Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets
REDHILL BIOPHARMA LTD. (RDHL) reported Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets of $665.00 thousand for the 12-month period ending 2024-12-31, per its 20-F filed 2025-04-10.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets · last filed 2025-04-10
| Period end | Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets 12 month |
|---|---|
| 2024-12-31 | $665.00K 20-F · filed 2025-04-10 |
| 2023-12-31 | $1.65M 20-F · filed 2025-04-10 |
| 2022-12-31 | $5.67M 20-F · filed 2025-04-10 |
| 2021-12-31 | $10.21M 20-F · filed 2024-04-08 |
| 2020-12-31 | $4.20M 20-F · filed 2023-04-28 |
| 2019-12-31 | $3.03M 20-F · filed 2022-03-17 |
| 2018-12-31 | $2.68M 20-F · filed 2021-03-18 |
| 2017-12-31 | $2.23M 20-F · filed 2020-03-04 |
| 2016-12-31 | $1.68M 20-F · filed 2019-02-26 |
| 2015-12-31 | $1.36M 20-F · filed 2018-02-22 |